Cancer

Theralase Technologies Inc. Advances Research on Laser-Activated Photodynamic Compounds for Cancer Treatment

Published in Cancer Weekly, August 7th, 2007

Theralase(TM) Technologies Inc. (TSX-V: TLT & OTC BB: TLTFF) announces that it has entered an agreement with University Health Network (UHN) and Ontario Centres of Excellence's (OCE) Centre of Excellence for Photonics, to expand their joint research and development of the Company's patented photodynamic compounds (PDC's), which are activated by its TLC-3000 PDC super-pulsed biofeedback laser technology.

Roger White, President and CEO of Theralase Technologies Inc. stated that, "This is a significant milestone for the Company, which further expands research and development of the combined photodynamic compounds and laser technology for the selective destruction of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2007-08-07)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry